Who Supplies Antitoxin to India from INDONESIA

To import finished pharmaceutical formulations containing antitoxins into India, the foreign manufacturer must obtain an Import License from the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with the Central Drugs Standard Control Organisation (CDSCO). This involves submitting an application in Form 40, along with necessary documents such as the Free Sale Certificate, Certificate of Pharmaceutical Product (CoPP), and stability data. The registration process typically takes 6-12 months. For antitoxin formulations under HS Code 30021220, specific requirements include evidence of clinical trials, safety and efficacy data, and compliance with Indian Pharmacopoeia standards. The importer must also obtain a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare.

Imported antitoxin formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product integrity in India's climate. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the product. Failure to meet these standards can result in rejection of the shipment.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for importing biological products, including antitoxin formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the volume of finished formulation imports. Bilateral agreements between India and Indonesia have facilitated smoother trade, but compliance with updated regulatory standards remains essential.

India imports finished antitoxin formulations due to the need for specialized products not manufactured domestically, such as certain patented or branded formulations and specific dosage forms. The domestic capacity to produce these formulations is limited, leading to a dependency on imports. The market size for antitoxin formulations in India is substantial, with a growing demand driven by increasing awareness and healthcare needs.

The Basic Customs Duty (BCD) for antitoxin formulations under HS Code 30021220 is 10%. The Social Welfare Surcharge (SWS) is 10% of the BCD, resulting in an additional 1% duty. The Integrated Goods and Services Tax (IGST) is 12% on the assessable value, which includes the CIF value plus applicable duties. There are no exemptions or preferential duty rates for imports from Indonesia. The total landed duty percentage is approximately 33%.

India sources antitoxin formulations from Indonesia due to competitive pricing, quality products, and compliance with international standards. Indonesia's pharmaceutical industry offers formulations that meet the specific needs of the Indian market, including certain patented or specialized products not available domestically. Other suppliers, such as China, Germany, and the United States, also serve the Indian market, but Indonesia's offerings are competitive in terms of both price and quality. Indonesia's share in India's antitoxin formulation imports is growing, reflecting its strengthening position as a supplier.

India imports antitoxin formulations from Indonesia due to the availability of specialized products not manufactured domestically, such as certain patented or branded formulations and specific dosage forms. Indonesia's pharmaceutical industry offers competitive pricing and products that meet international quality standards, making it an attractive source for these formulations.

Compared to other origins like China, the European Union, and the United States, Indonesia offers competitive pricing and quality for antitoxin formulations. While China may offer lower prices, concerns about quality and regulatory compliance can be issues. The European Union and the United States provide high-quality products but at higher prices. Indonesia's unique advantage lies in its ability to offer quality products at competitive prices, with a focus on formulations that meet the specific needs of the Indian market.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to regulatory changes and shipping delays. To mitigate these risks, importers should diversify suppliers, monitor currency trends, stay updated on regulatory changes, and maintain robust quality assurance processes.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP) to manage financial risk.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to optimize inventory and cost.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.

1. 1DGFT Import License: Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Submit application in Form 40, including Free Sale Certificate, CoPP, and stability data.
3. 3Drug Import License: Apply for a license under the Drugs and Cosmetics Act, 1940.
4. 4No Objection Certificate (NOC): Obtain NOC from the Ministry of Health and Family Welfare.
5. 5Customs Broker: Engage a licensed customs house agent for clearance.